LTGO
NASD Latigo Biotherapeutics, Inc.$0.0000 ↓ -15.9000 (-100.00%) Trading Down from the previous close of $15.9000
- YTD change
- N/A
- vs 20-day SMA
- N/A
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-2.35 (-12.88%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $25.9300
- LTGO is down 100% since the beginning of the year
- LTGO is down 100% over the past 12 months
- LTGO is down 100% over the past 1 month
- 2% of all LTGO investors are betting against LTGO
LTGO reads poor: the 12-month move is -12.9%.
- Previous minute
- N/A
- Last hour
- N/A
- Last 5 days
- N/A
- vs 8-day SMA
- N/A
No alerts for LTGO in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.
Competitor comparison
No peer group available for this symbol.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.